Drug intelligence / Profile preview

GI-128

Development stage: Preclinical
Lead developer: GI Innovation
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GI-128 is a bispecific macrophage-engaging antibody developed by GI Innovation. It is composed of an anti-PD-L1 single domain antibody (sdAb) and an anti-LILRBs sdAb, specifically targeting LILRB1, LILRB2, and LILRB4. By simultaneously binding to PD-L1 on tumor cells and LILRB receptors on myeloid cells, GI-128 aims to reprogram immunosuppressive M2 tumor-associated macrophages into immunostimulatory M1 phenotypes and enhance macrophage-mediated phagocytosis of tumor cells. This approach is intended to overcome resistance to traditional immune checkpoint inhibitors in PD-L1-positive tumors.

Targets

LILRB (Leukocyte immunoglobulin-like receptor B family)CD274 (Programmed cell death protein 1 ligand 1)LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)LILRB4

Beyond the preview

Go deeper on GI-128.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GI-128.